Why Nanobiotix S.A.’s (NBTX) Stock Is Down 6.26%
As of Thursday, July 16, Nanobiotix S.A.’s NBTX share price has dipped by 6.26%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Commentary & Analysis
Why Nanobiotix S.A.’s (NBTX) Stock Is Down 5.14%
As of Wednesday, July 15, Nanobiotix S.A.’s NBTX share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Nanobiotix S.A.’s (NBTX) Stock Is Up 7.08%
As of Tuesday, July 14, Nanobiotix S.A.’s NBTX share price has surged by 7.08%, which has investors questioning if this is right time to sell.Michael Rose
Why Nanobiotix S.A.’s (NBTX) Stock Is Down 6.33%
As of Tuesday, July 07, Nanobiotix S.A.’s NBTX share price has dipped by 6.33%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Nanobiotix S.A.’s (NBTX) Stock Is Up 6.22%
As of Monday, July 06, Nanobiotix S.A.’s NBTX share price has surged by 6.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | NBTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,252.9 | $292.6 | 55% |
|
| Shares Out (Mil) | 56.6 | 54.4 | 50% |
|
| Institutional Ownership | 83.4% | 93.2% | 51% |
|
| Float (Mil) | 31.3 | 40.2 | 37% |
|
| Beta | 0.58 | 0.94 | 34% |
|
| Avg Daily Volume (000s) | 178 | 544 | 42% |
|
| Price Change (52-week) |
410.6% | 59.7% | 99% |
|
| Growth | NBTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 68.7% | 13.6% | 97% |
|
| Net Income (5yr) | 7.3% | (10.1%) | 51% |
|
| EPS (5yr) | 19.0% | 16.0% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (55.5%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NBTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $38 | $37 | 18% |
|
| Net Income (TTM) (Mil) | ($28) | ($43) | 21% |
|
| EPS (TTM) | ($0.588) | ($1.400) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($39) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $2 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $107 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $1,685 | $164 | 47% |
|
| Valuation | NBTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NBTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.2% | 96% |
|
| Net Margin | (73.5%) | (75.9%) | 9% |
|
| ROA | (37.7%) | (47.5%) | 14% |
|
| ROE | 33.6% | (55.0%) | 89% |
|
| Liabilities to Assets | 224.7% | 29.6% | 99% |
|
| F-Score | 4 | 3 | 33% |
|
Nanobiotix S.A. did not pass any screens on 8/21/2026.
